NCT01997632View on ClinicalTrials.gov

Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)

a single dose m-IPV2 HD (study vaccine), 0,5ml

BIOLOGICAL

a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).

a single 0.5 ml dose Imovax Polio (control vaccine)

Trial Locations (1)

9000

Ghent University Hospital, Ghent

All Listed Sponsors
lead

University Hospital, Ghent

OTHER

NCT01997632 - Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults | Biotech Hunter | Biotech Hunter